Fingolimod - relapsing-remitting multiple sclerosis (RRMS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/336317/2020 EMEA/H/C/005191 Fingolimod Accord (fingolimod (...) ) An overview of Fingolimod Accord and why it is authorised in the EU What is Fingolimod Accord and what is it used for? Fingolimod Accord is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (RRMS). ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods with milder or no symptoms (remissions). Fingolimod Accord is used when

Ozanimod (Zeposia) - relapsing-remitting multiple sclerosis (RRMS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/171870/2020 EMEA/H/C/004835 Zeposia (ozanimod) An overview (...) of Zeposia and why it is authorised in the EU What is Zeposia and what is it used for? Zeposia is a medicine used to treat adults with relapsing-remitting multiple sclerosis (RRMS), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms (remission). It is used in patients with active disease, which means that patients have relapses or signs of active inflammation on scans. Zeposia contains the active substance ozanimod. How is Zeposia used? Zeposia can only be obtained

EAN guideline on palliative care of people with severe, progressive multiple sclerosis EAN guideline on palliative care of people with severe, progressive multiple sclerosis A. Solari a , A. Giordano a,b , J. Sastre-Garriga c ,S.K€ opke d,e , A. C. Rahn e , I. Kleiter f , K. Aleksovska g , M. A. Battaglia h , J. Bay i , M. Copetti j , J. Drulovic k , L. Kooij l , J. Mens l , E. R. Meza Murillo c , I. Milanov m , R. Milo n,o , T. Pekmezovic p , J. Vosburgh q , E. Silber r , S. Veronese s , F (...) . Patti t , R. Voltz u,v , D. Oliver w and on behalf of the guideline task force , * a Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; b Department of Psychology, University of Turin, Turin, Italy; c Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Universitat Aut onoma de Barcelona, Barcelona, Spain; d Institute of Clinical Nursing Science, University of Cologne, Cologne; e Institute

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try (...) Stutters 1 , David MacManus 1 , Ferran Prados 1, 4, 5 , Ian Marshall 2 , Bhavana Solanky 1 , Rebecca S Samson 1 , Frederik Barkhof 1, 4, 6 , Sebastien Ourselin 7 , Marie Braisher 1 , Moira Ross 3 , Gina Cranswick 3 , Sue H Pavitt 8 , Sharmilee Gnanapavan 9 , Gavin Giovannoni 9 , Claudia AM Gandini Wheeler-Kingshott 1, 10 , Clive Hawkins 11 , Basil Sharrack 12 , Roger Bastow 13 , Christopher J Weir 3 , Nigel Stallard 14 , Siddharthan Chandran 2 , Jeremy Chataway 1, 15, * 1 Queen Square Multiple

Siponimod (Mayzent) - multiple sclerosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

Ozanimod (Zeposia) - To treat relapsing forms of multiple sclerosis Drug Approval Package: ZEPOSIA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPOSIA Company: Celgene Corporation Application Number: 209899 Approval Date: 03/20/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

Fampridine (Fampyra) - For the improvement of walking in adult patients with multiple sclerosis 1 Published 13 April 2020 1 SMC2253 fampridine 10mg prolonged-release tablet (Fampyra®) Biogen Idec Ltd 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a second resubmission fampridine (Fampyra (...) ® ) is accepted for use within NHSScotland. Indication under review: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7). In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 19 February 2020 www.nice.org.uk/guidance/ta624 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 18Contents Contents 1 Recommendations 4 2 Information about peginterferon beta-1a 5 Marketing

Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease modifying drugs for treatment of primary progressive (...) multiple sclerosis: A health technology assessment Order Download: Key message We have systematically collected and reviewed the evidence for clinical efficacy for disease modifying treatments for PPMS. We included three randomised placebo-controlled trials that each compare the effect of one medication (either fingolimod, ocrelizumab or rituximab, respectively) with placebo. For each of the three drugs, we calculated the risk ratios for confirmed disease progression. We also report results in the form

Siponimod (Mayzent) - multiple sclerosis (MS) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/629863/2019 EMEA/H/C/004712 Mayzent (siponimod) An overview of Mayzent and why

Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 13/02/2020 Relative effectiveness assessment of pharmaceutical technologies SIPONIMOD FOR THE TREATMENT OF ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (...) in the production of this assessment have declared that they have no conflicts of interest in relation to the technology assessed according to the EUnetHTA declaration of interest and confidentiality undertaking form. How to cite this assessment Please cite this assessment as follows: EUnetHTA PTJA08. Authoring Team. Relative effectiveness assessment of pharmaceutical technologies. Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced

Ocrelizumab (Ocrevus) - early primary progressive multiple sclerosis (PPMS) 1 Published 13 January 2020 1 SMC2223 ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) Roche Products Ltd 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process ocrelizumab (Ocrevus ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. In a randomised, double-blind, phase III study, the risk of disability progression was significantly reduced in patients who received ocrelizumab compared with placebo

Cladribine for treating relapsing–remitting multiple sclerosis Cladribine for treating relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 19 December 2019 www.nice.org.uk/guidance/ta616 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration (...) to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cladribine for treating relapsing–remitting multiple sclerosis (TA616) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 Information about cladribine 6 Marketing authorisation indication 6 Dosage

Fampridine (Fampyra) - multiple sclerosis Final Appraisal Recommendation Advice No: 1919 – December 2019 Fampridine (Fampyra ® ) 10 mg prolonged-release tablets Submission by Biogen Idec Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3942), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR (...) , clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Fampridine (Fampyra ® ) is recommended as an option for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4 to 7

Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS) Cognitive Rehabilitation for Attention and Memory in People With Multiple Sclerosis: A Randomized Controlled Trial (CRAMMS) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519890378 2019 Nov 26 [Online ahead of print] Cognitive Rehabilitation for Attention and Memory in People With Multiple Sclerosis: A Randomized Controlled Trial (CRAMMS) , , , , , , , , , Collaborators, Affiliations Expand Collaborators CRAMMS Trial Collaborative

Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above

Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies SHTG Advice | 1 SHTG Advice Number 07 October 2019 In response to an enquiry from the Strategic Planning and Clinical Priorities Team, Planning and Quality Division, Scottish Government Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding (...) to high-efficacy disease modifying therapies Advice for NHSScotland Where patients understand and are willing to accept the demands, risks and uncertainties of treatment, autologous haematopoietic stem cell transplant (AHSCT) should be considered as a treatment option for patients with relapsing-remitting multiple sclerosis (RRMS) who have evidence of significant inflammatory disease activity that has not responded to adequate treatment with licensed high-efficacy disease modifying therapies (DMTs

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE (...) phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis.We did a 24-month, multicentre, double-blind, double-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and clinical practices in 21 countries. Participants were aged 18-55 years, had multiple sclerosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent with multiple

Disease modifying treatments for relapsing remitting multiple sclerosis. A health economic evaluation Disease modifying treatments for relapsing remitting multiple sclerosis - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease modifying treatments for relapsing remitting multiple sclerosis Order Download: Key message The Norwegian (...) Institute of Public health has previously assessed the efficacy, safety and cost effectiveness of drugs for relapsing remitting multiple sclerosis. In this report, three new drugs (cladribine, ocrelizumab and rituximab) are included. Effectiveness, safety and legal aspects are reported in a separate publication, as is ethical considerations. This report assesses the included drugs in light of the Norwegian priority setting criteria (benefit, resource use and disease severity). Relapsing remitting

Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment. - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease-modifying treatments for relapsing remitting multiple sclerosis (...) , including rituximab. A health technology assessment. Order Download: Key message We have systematically collected and reviewed the evidence for clinical effectiveness and general safety issues for disease modifying treatments for relapsing remitting multiple sclerosis, synthesised evidence from randomised controlled trials and non-randomised registry-based studies using network meta-regression, and carefully interpreted the findings. We included rituximab in our analysis as it is used off-label